This article is more than 5 years old. Information may no longer be current.

Ophthotech begins enrollment in trial of anti-PDGF for wet AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ophthotech Corp. announced in a press release that it has begun enrolling patients in a phase 3 clinical trial where Fovista, an anti-platelet-derived growth factor, is being studied with an anti-vascular endothelial growth factor for treating patients diagnosed with wet age-related macular degeneration.

The global Fovista phase 3 program consists of three clinical trials evaluating the safety and efficacy of this anti-PDGF/anti-VEGF combination, the company said in the press release. Ophthotech expects to enroll 1,866 patients at up to 225 centers around the world.